Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

505
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
505
Pharmacovigilance01:19

Pharmacovigilance

805
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
805
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Therapeutic Index01:13

Therapeutic Index

4.2K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE.

Circulation. Population health and outcomes·2026
Same author

Unmet needs poststroke and associated factors: A systematic review and meta-analysis.

Rehabilitation psychology·2026
Same author

PERKS-International: A Randomized Controlled Trial Testing the Efficacy of an mHealth Application to Reduce Risk Factors for the Primary Prevention of Stroke.

Stroke·2026
Same author

Polygenic Risk Identifies Older Adults Who May Benefit From Aspirin for the Primary Prevention of Ischemic Stroke.

Stroke·2026
Same author

Statistical analysis plan for Love Your Brain: a multi-arm randomised controlled trial of a stroke prevention digital platform.

Trials·2026
Same author

Antibiotic use in older Australians with and without dementia in primary care.

Age and ageing·2026
Same journal

Feasibility of early double sequential defibrillation in out-of-hospital cardiac arrest: the double-D randomised pilot trial.

Heart (British Cardiac Society)·2026
Same journal

Correspondence on 'When a patent foramen ovale becomes pathological' by Saji and Ohara.

Heart (British Cardiac Society)·2026
Same journal

Cost-effectiveness of N-terminal pro-B-type natriuretic peptide thresholds for echocardiography referral in primary care heart failure management.

Heart (British Cardiac Society)·2026
Same journal

Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis.

Heart (British Cardiac Society)·2026
Same journal

Importance of rating: the impact of establishing age and sex normative values for left ventricular strain rate.

Heart (British Cardiac Society)·2026
Same journal

Man in his 40s with palpitations.

Heart (British Cardiac Society)·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

Aspirin: latest evidence and developments.

Mark R Nelson1, J Andrew Black2

  • 1Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia Mark.Nelson@utas.edu.au.

Heart (British Cardiac Society)
|July 29, 2024
PubMed
Summary
This summary is machine-generated.

Aspirin, initially an anti-inflammatory drug, is now a key prophylactic for major adverse cardiovascular events (MACE). Ongoing research explores its future potential in cancer chemoprevention and other diseases.

Keywords:
cardiovascular diseasestreatment outcome

More Related Videos

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

2.7K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.5K

Related Experiment Videos

Last Updated: Jun 18, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

2.7K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.5K

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Oncology

Background:

  • Aspirin, a foundational pharmaceutical, was initially developed for pain and inflammation.
  • It was later discovered to be effective in preventing major adverse cardiovascular events (MACE).
  • Current use of aspirin for MACE prevention is evaluated against its efficacy/safety profile in populations with declining MACE rates and competing therapies.

Purpose of the Study:

  • To review the established and emerging roles of aspirin in disease prevention.
  • To discuss the evolving clinical context for aspirin's use in cardiovascular and oncological chemoprophylaxis.
  • To highlight the ongoing clinical research investigating aspirin's future therapeutic applications.

Main Methods:

  • Literature review of aspirin's pharmacological properties and clinical applications.
  • Analysis of epidemiological trends in major adverse cardiovascular events.
  • Examination of current therapeutic alternatives and emerging research in cancer chemoprevention.

Main Results:

  • Aspirin remains a significant agent for preventing major adverse cardiovascular events (MACE).
  • Its efficacy and safety balance is crucial in contemporary populations with decreasing MACE incidence.
  • Emerging research suggests potential roles for aspirin in cancer chemoprophylaxis and as an adjunct therapy.

Conclusions:

  • Aspirin's utility extends beyond its anti-inflammatory origins to cardiovascular event prophylaxis.
  • The future clinical relevance of aspirin will be influenced by its performance against competing treatments and its potential in new disease areas.
  • Continued clinical research is essential to fully define aspirin's future therapeutic landscape, including its role in cancer prevention.